Therapy Areas: Vaccines
Recbio declares completion of subject enrolment and first dose vaccination in phase III clinical trial of recombinant HPV 9-valent vaccine
10 August 2022 -

Vaccine company Jiangsu Recbio Technology Co Ltd (Recbio) (HK:02179) announced on Tuesday that it has recently completed the subject enrolment and first dose vaccination in respect of immuno-bridging study of its recombinant HPV 9-valent vaccine, REC603, in younger-age groups and the study to compare the immunogenicity between REC603 and Gardasil 9.

In conjunction, follow-up on the subjects of REC603's efficacy trial is being conducted in accordance with the clinical protocol.

The company said its phase III clinical trial of REC603 in China is comprised of three parts: the efficacy trial, the immuno-bridging trial in younger-age groups, and the immunogenicity comparative trial with Gardasil 9, with a multi-centre, randomised, blinded and parallel controlled design and with a total size of 16,050 subjects.

According to Recbio, HPV 9-valent vaccines can prevent approximately 90% of cervical cancers and 90% of anal and genital warts. It is widely regarded as the most effective vaccine against HPV infections. Completed phase I clinical data of REC603 shows that it is safe and well tolerated with a favourable immunogenicity profile.